EA200501768A1 - Вич-пролекарства, способные расщепляться под действием cd26 - Google Patents

Вич-пролекарства, способные расщепляться под действием cd26

Info

Publication number
EA200501768A1
EA200501768A1 EA200501768A EA200501768A EA200501768A1 EA 200501768 A1 EA200501768 A1 EA 200501768A1 EA 200501768 A EA200501768 A EA 200501768A EA 200501768 A EA200501768 A EA 200501768A EA 200501768 A1 EA200501768 A1 EA 200501768A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
alkyl group
prodrugs
acid
alkyl
Prior art date
Application number
EA200501768A
Other languages
English (en)
Other versions
EA009727B1 (ru
Inventor
Херман Аугустинус Де Кок
Пит Том Берт Поль Вигеринк
Ян Бальзарини
Original Assignee
Тиботек Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикалз Лтд. filed Critical Тиботек Фармасьютикалз Лтд.
Publication of EA200501768A1 publication Critical patent/EA200501768A1/ru
Publication of EA009727B1 publication Critical patent/EA009727B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

В настоящем изобретении предлагаются новые пролекарства, которые представляют собой конъюгаты терапевтического соединения и пептида, при этом конъюгат способен расщепляться под действием дипептидилпептидазы, более предпочтительно под действием CD26, известной также как DPPIV (дипептидиламинопептидаза IV). Пролекарства по настоящему изобретению имеют формулу (I) или представляют собой его стереоизомерные формы и его соли, где n составляет от 1 до 5; Y обозначает пролин, аланин, гидроксипролин, дигидроксипролин, тиазолидинкарбоновую кислоту (тиопролин), дегидропролин, пипеколиновую кислоту (L-гомопролин), азетидинкарбоновую кислоту, азиридинкарбоновую кислоту, глицин, серин, валин, лейцин, изолейцин и треонин; X выбирают из любой аминокислоты с D- или L-конфигурацией; X и Y в каждом повторе фрагмента [Y-X] выбирают независимо один от другого и независимо от других повторов; Z обозначает прямую связь или бивалентную насыщенную углеводородную группу с прямой или разветвленной цепью, содержащую от 1 до 4 атомов углерода; Rобозначает арильную, гетероарильную группу, арилоксигруппу, гетероарилоксигруппу, арилокси Cалкильную группу, гетероциклоалкилоксигруппу, гетероциклоакил Cалкоксигруппу, гетероарилокси Cалкильную группу, гетероарил Cалкилоксигруппу; Rобозначает арил Cалкильную группу; Rобозначает Cалкильную, Cалкенильную или Cциклоакил Cалкильную группу; Rобозначает водород или Cалкильную группу. В настоящем изобретении предлагается также применение указанных пролекарств в качестве лекарственных средств, а также способ получения указанных пролекарств.
EA200501768A 2003-05-08 2004-05-10 Вич-пролекарства, способные расщепляться под действием cd26 EA009727B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310593.9A GB0310593D0 (en) 2003-05-08 2003-05-08 Peptidic prodrugs
PCT/EP2004/050753 WO2004099135A2 (en) 2003-05-08 2004-05-10 Hiv prodrugs cleavable by cd26

Publications (2)

Publication Number Publication Date
EA200501768A1 true EA200501768A1 (ru) 2006-04-28
EA009727B1 EA009727B1 (ru) 2008-02-28

Family

ID=9957688

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501768A EA009727B1 (ru) 2003-05-08 2004-05-10 Вич-пролекарства, способные расщепляться под действием cd26

Country Status (22)

Country Link
US (2) US20080214648A1 (ru)
EP (2) EP1620130A1 (ru)
JP (2) JP2007526872A (ru)
KR (1) KR20060008300A (ru)
CN (1) CN1784244A (ru)
AP (1) AP2005003465A0 (ru)
AT (1) ATE375172T1 (ru)
AU (2) AU2004235988A1 (ru)
BR (1) BRPI0410158A (ru)
CA (2) CA2525191A1 (ru)
DE (1) DE602004009435T2 (ru)
DK (1) DK1624897T3 (ru)
EA (1) EA009727B1 (ru)
ES (1) ES2295879T3 (ru)
GB (1) GB0310593D0 (ru)
MX (1) MXPA05012019A (ru)
NO (1) NO20055826L (ru)
NZ (1) NZ543946A (ru)
PT (1) PT1624897E (ru)
UA (1) UA82221C2 (ru)
WO (2) WO2004098644A1 (ru)
ZA (1) ZA200509940B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005319578A1 (en) 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
DK1831361T3 (da) 2004-12-23 2012-05-14 Campina Nederland Holding Bv Proteinhydrolysat beriget med peptider, som inhiberer DPP-IV, og deres anvendelse
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
CA2647835A1 (en) 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
JP2010527377A (ja) 2007-05-17 2010-08-12 ネオプロ ラブス，エルエルシー ペプチドの結晶形および非結晶形
WO2009058662A2 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
WO2009129305A2 (en) 2008-04-15 2009-10-22 Tsrl, Inc. Prodrugs of neuraminidase inhibitors
CA2737253C (en) * 2008-09-12 2017-08-15 Cadila Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv (dp-iv) compounds
WO2010053550A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
CA2747195A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
EP2566494B1 (en) * 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
CN105683180B (zh) 2013-11-05 2020-01-21 阿斯利康(瑞典)有限公司 Nmda拮抗剂前药
EP3192794A4 (en) * 2014-09-11 2018-06-27 Shionogi & Co., Ltd. Sustained hiv protease inhibitor
EP3197912B1 (en) * 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
KR102633963B1 (ko) * 2015-05-29 2024-02-05 애로우헤드 파마슈티컬스 인코포레이티드 생물학적으로 절단가능한 테트라펩티드 연결제
KR102509006B1 (ko) 2017-04-01 2023-03-13 에이브이엠 바이오테크놀로지, 엘엘씨 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체
CA3067674A1 (en) * 2017-06-29 2019-01-03 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CN111233955B (zh) * 2020-02-28 2022-06-10 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55431A (en) * 1978-08-24 1982-07-30 Yeda Res & Dev Anthracycline type antibiotics,their preparation and pharmaceutical compositions comprising them
WO1987007276A1 (en) * 1986-05-30 1987-12-03 Fuji Kagaku Kogyo Kabushiki Kaisha Novel 5-fluorouridine compounds and process for their preparation
US5627035A (en) * 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5843946A (en) * 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6046190A (en) * 1992-08-25 2000-04-04 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
US5830897A (en) * 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
SI0769967T1 (sl) * 1994-08-19 2008-06-30 Wallone Region Konjugati vsebujoäśi protitumorna sredstva in njihova uporaba
WO1997000268A1 (en) * 1995-06-15 1997-01-03 Pfizer Inc. Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide
CZ389398A3 (cs) * 1996-05-29 1999-07-14 Prototek, Inc. Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5783689A (en) * 1996-11-12 1998-07-21 University Of Notre Dame Antibacterial and antifungal nucleosides
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
CA2401340A1 (en) * 2000-02-28 2001-09-07 The University Of British Columbia Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors
CA2411545A1 (en) * 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
US6849622B2 (en) * 2000-10-06 2005-02-01 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002360487A1 (en) * 2001-12-04 2003-06-17 Ashim K. Mitra Acyclovir-peptide analogs
AU2003296601A1 (en) * 2002-12-10 2004-06-30 F. Hoffmann-La Roche Ag Antiviral nucleoside derivatives
AU2004212786A1 (en) * 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting HIV replication

Also Published As

Publication number Publication date
AU2004236371A1 (en) 2004-11-18
PT1624897E (pt) 2008-01-17
DK1624897T3 (da) 2008-02-11
DE602004009435T2 (de) 2008-07-24
NZ543946A (en) 2008-09-26
JP2007526872A (ja) 2007-09-20
AU2004236371B2 (en) 2009-12-17
US20070275900A1 (en) 2007-11-29
JP2006525235A (ja) 2006-11-09
CA2517338A1 (en) 2004-11-18
US8236756B2 (en) 2012-08-07
ES2295879T3 (es) 2008-04-16
UA82221C2 (ru) 2008-03-25
CN1784244A (zh) 2006-06-07
EA009727B1 (ru) 2008-02-28
ZA200509940B (en) 2007-04-25
AP2005003465A0 (en) 2005-12-31
NO20055826D0 (no) 2005-12-08
WO2004099135A3 (en) 2005-02-17
NO20055826L (no) 2006-02-08
EP1624897B1 (en) 2007-10-10
EP1620130A1 (en) 2006-02-01
US20080214648A1 (en) 2008-09-04
ATE375172T1 (de) 2007-10-15
BRPI0410158A (pt) 2006-05-16
EP1624897A2 (en) 2006-02-15
KR20060008300A (ko) 2006-01-26
AU2004235988A1 (en) 2004-11-18
WO2004099135A2 (en) 2004-11-18
GB0310593D0 (en) 2003-06-11
CA2525191A1 (en) 2004-11-18
DE602004009435D1 (de) 2007-11-22
MXPA05012019A (es) 2006-02-03
WO2004098644A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
EA200501768A1 (ru) Вич-пролекарства, способные расщепляться под действием cd26
RU2003105464A (ru) Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов
Yiotakis et al. Phosphinic peptides: Synthetic approaches and biochemical evaluation as Zn-metalloprotease inhibitors
Dembitsky et al. Synthesis and biological activity of α-aminoboronic acids, amine-carboxyboranes and their derivatives
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RU2003110960A (ru) Новые ингибиторы дипептидилпептидазы iv и их применение для понижения кровяного давления
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
RU2013144368A (ru) Пролекарства действующих веществ гетероциклическими линкерами
EP2341065A3 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UA102677C2 (ru) Хиноксалинсодержащие соединения как ингибиторы вируса гепатита с
EP0787010A1 (en) Amidino and guanidino substituted inhibitors of trypsin-like enzymes
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
US5639739A (en) Imidazole containing aminoboronic acids
EP0696199A1 (en) Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
DE60326128D1 (de) Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen
FR2879202B1 (fr) Nouveaux ligands multimeriques de cd40, leur procede de preparation et leur utilisation pour la preparation de medicaments

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU